First Study Launches

From Vision to Action: CANDO Launches First Major Study

January 2026, Fort Collins, CO, USA

Following our successful strategic planning in January, we are thrilled to announce that the first CANDO research project is officially underway. This inaugural study tackles one of the most pressing topics in modern veterinary medicine: the long-term joint health of dogs receiving anti-NGF therapies like Bedinvetmab (Librela™).

While these therapies provide incredible pain relief for many pets, the scientific community is still learning how they impact the structural "homeostasis" of the joint. CANDO is leading the way as the first network to histologically examine joint tissues from dogs with naturally occurring osteoarthritis who have been treated with these medications.

Find out more about this study here.